RxSight, Inc. (NASDAQ:RXST) Given Average Recommendation of "Buy" by Analysts

RxSight, Inc. (NASDAQ:RXST - Get Free Report) has earned a consensus recommendation of "Buy" from the eight brokerages that are covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $61.63.

Several analysts recently issued reports on the stock. Needham & Company LLC restated a "buy" rating and set a $66.00 target price on shares of RxSight in a research report on Friday, September 13th. Jefferies Financial Group initiated coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a "buy" rating and a $72.00 price objective for the company. Stifel Nicolaus decreased their target price on RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, August 6th. Oppenheimer cut their price target on RxSight from $72.00 to $65.00 and set an "outperform" rating for the company in a report on Tuesday, August 6th. Finally, Wells Fargo & Company decreased their price objective on RxSight from $68.00 to $54.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 6th.

Insider Activity

In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction on Friday, September 20th. The shares were sold at an average price of $53.19, for a total value of $164,889.00. Following the sale, the insider now directly owns 42,246 shares in the company, valued at approximately $2,247,064.74. The trade was a 6.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jesse Anderson Corley acquired 11,111 shares of the company's stock in a transaction on Tuesday, November 12th. The shares were bought at an average cost of $45.37 per share, with a total value of $504,106.07. Following the acquisition, the director now directly owns 468,571 shares in the company, valued at approximately $21,259,066.27. The trade was a 2.43 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 62,702 shares of company stock worth $3,059,197 over the last ninety days. Corporate insiders own 9.36% of the company's stock.

Institutional Investors Weigh In On RxSight

Several large investors have recently made changes to their positions in RXST. RA Capital Management L.P. increased its position in RxSight by 6.0% in the third quarter. RA Capital Management L.P. now owns 3,916,825 shares of the company's stock worth $193,609,000 after purchasing an additional 222,000 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of RxSight by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company's stock worth $78,634,000 after buying an additional 40,500 shares during the last quarter. State Street Corp raised its position in shares of RxSight by 8.3% during the 3rd quarter. State Street Corp now owns 817,671 shares of the company's stock valued at $40,417,000 after buying an additional 62,349 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of RxSight by 17.7% in the 3rd quarter. Geode Capital Management LLC now owns 817,117 shares of the company's stock valued at $40,398,000 after acquiring an additional 122,775 shares during the last quarter. Finally, Driehaus Capital Management LLC grew its position in RxSight by 74.9% in the second quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company's stock worth $42,490,000 after acquiring an additional 302,367 shares in the last quarter. 78.78% of the stock is owned by institutional investors.

RxSight Price Performance

Shares of NASDAQ:RXST opened at $46.06 on Wednesday. The stock's 50-day simple moving average is $49.20 and its two-hundred day simple moving average is $52.57. RxSight has a 52-week low of $28.88 and a 52-week high of $66.54.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.